EXTON, Pa., Feb. 7, 2013 /PRNewswire/-- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds the following key results, according to a recent BioTrends' study, ChartTrends: Renal Anaemia in Chronic Kidney Disease - Non-Dialysis (CKD-ND) and Dialysis, of 962 EU5 dialysis patient charts and 928 EU5 CKD-ND patient charts:
Erythropoiesis-stimulating agents (ESAs) treatment prevalence in both haemodialysis (HD) and peritoneal dialysis (PD) patient populations has declined from two years ago and the decline of 9 percent in HD reached statistical significance
Surveyed nephrologists significantly over-estimate the haemoglobin level at which they initiate ESAs in dialysis; this finding is pronounced in every EU5 country with the exception of Italy
ESA treatment prevalence in the Stage 4 CKD-ND patient population is up 12 percent from two years ago, according to 382 Stage 4 CKD-ND patient charts
Nephrologists significantly underestimate their use of ESAs in Stage 4 (predominately in France and Italy) and directionally in Stage 5 non-dialysis (significantly in Italy)
Aranesp (Amgen), Eprex/Erypo (Janssen-Cilag), NeoRecormon (Roche) and Mircera (Roche) and collectively ESA biosimilars are leading the dialysis market. In particular, ESA biosimilars in the dialysis population have reached mid-teen double-digit patient share, but use is much less in the CKD-ND patient population
HD IV iron treatment prevalence has remained flat from two years ago, but nephrologists over-estimate the use of IV iron in PD and under-estimate the use of oral iron in PD
In CKD-ND, Venofer (Vifor Pharmaceuticals), Ferinject (Vifor Pharmaceuticals) and Ferrlecit (Sanofi) lead this space. Rienso, which recently launched in EU5 from Takeda Pharmaceuticals (developed by AMAG Pharmaceuticals), has captured minimal share at this point
"ESA cardiovascular warnings and cost containment pressures may be the reason for these declining ESA treatment prevalences found in the dialysis patient charts," said Rob Dubman , BioTrends' Director of Nephrology.
ChartTrends: Renal Anaemia in Chronic Kidney Disease - Non-Dialysis (CKD-ND) and Dialysis is a syndicated report series, in which 210 nephrologists provided patient chart data on 962 dialysis patients in the EU5 and 191 nephrologists provided patient chart data on 928 CKD-ND patients in the EU5 in the most recent wave of research to uncover the actual management related to renal anaemia. Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers.
The study also evaluated referral patterns, co-morbidities, blood transfusions, hospitalizations and a host of other patient demographics and laboratory data. BioTrends is publishing ChartTrends: Renal Anemia in dialysis and CKD-ND reports later this year in the US. Additional ChartTrends Dialysis reports have been published in China and Latin America (Brazil, Argentina and Mexico).
About BioTrends Research GroupBioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com. About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.All company, brand, or product names contained in this document may be trademarks of their respective holders.
For more information, contact: BioTrends Research Group, LLC Decision Resources GroupRob Dubman
781-993-2597 email@example.com firstname.lastname@example.org
Related medicine technology :1
|SOURCE BioTrends Research Group|
Copyright©2012 PR Newswire.
All rights reserved
. EU5 Nephrologists Report a Stabilization of Phosphate Binder Treatment Prevalence in the Late-Stage CKD and Dialysis Patient Populations2
. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 203
. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector4
. WuXi PharmaTech Files 2011 Annual Report on Form 20-F5
. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events6
. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.7
. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 20128
. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 20129
. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter10
. CryoLife Reports Record Quarterly Revenues in First Quarter of 201211
. Chindex International, Inc. to Report First Quarter 2012 Financial Results